- Home
- ICU vs GLTO Comparison
ICU vs GLTO Comparison
Compare ICU & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- GLTO
- Stock Information
- Founded
- ICU 2018
- GLTO 2011
- Country
- ICU United States
- GLTO Denmark
- Employees
- ICU N/A
- GLTO N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- GLTO Health Care
- Exchange
- ICU Nasdaq
- GLTO Nasdaq
- Market Cap
- ICU 10.3M
- GLTO 9.5M
- IPO Year
- ICU N/A
- GLTO 2020
- Fundamental
- Price
- ICU $2.19
- GLTO $6.36
- Analyst Decision
- ICU
- GLTO Buy
- Analyst Count
- ICU 0
- GLTO 1
- Target Price
- ICU N/A
- GLTO $10.00
- AVG Volume (30 Days)
- ICU 24.8K
- GLTO 15.9K
- Earning Date
- ICU 11-13-2024
- GLTO 11-01-2024
- Dividend Yield
- ICU N/A
- GLTO N/A
- EPS Growth
- ICU N/A
- GLTO N/A
- EPS
- ICU N/A
- GLTO N/A
- Revenue
- ICU $68,000.00
- GLTO N/A
- Revenue This Year
- ICU N/A
- GLTO N/A
- Revenue Next Year
- ICU $344.44
- GLTO N/A
- P/E Ratio
- ICU N/A
- GLTO N/A
- Revenue Growth
- ICU N/A
- GLTO N/A
- 52 Week Low
- ICU $1.88
- GLTO $6.36
- 52 Week High
- ICU $42.93
- GLTO $23.50
- Technical
- Relative Strength Index (RSI)
- ICU 25.85
- GLTO 30.60
- Support Level
- ICU $1.88
- GLTO $6.69
- Resistance Level
- ICU $2.81
- GLTO $6.94
- Average True Range (ATR)
- ICU 0.30
- GLTO 0.33
- MACD
- ICU -0.04
- GLTO 0.13
- Stochastic Oscillator
- ICU 18.58
- GLTO 0.00
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.